Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Human-to-Cattle <i>Mycobacterium tuberculosis</i> Complex Transmission in the United States.

Frontiers in veterinary science·2021

Same author

Cost-benefit analysis of vaccination against Mycobacterium avium ssp. paratuberculosis in dairy cattle, given its cross-reactivity with tuberculosis tests.

Journal of dairy science·2015

Same author

Equine platelet CD62P (P-selectin) expression: a phenotypic and morphologic study.

Veterinary immunology and immunopathology·2003

Same author

Impaired Th2 development and increased mortality during Schistosoma mansoni infection in the absence of CD40/CD154 interaction.

Journal of immunology (Baltimore, Md. : 1950)·2002

Same author

Central role for interleukin-4 in regulating nitric oxide-mediated inhibition of T-cell proliferation and gamma interferon production in schistosomiasis.

Infection and immunity·2001

Search research articles

Related Experiment Video

Updated: May 28, 2026

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

Paratuberculosis vaccination.

Elisabeth A Patton¹

¹Wisconsin Department of Agriculture, Trade and Consumer Protection, Division of Animal Health, PO Box 2811, Madison, WI 53708-8911, USA. elisabeth.patton@wi.gov

The Veterinary Clinics of North America. Food Animal Practice

|October 26, 2011

Summary

This summary is machine-generated.

Mycopar vaccine reduces Johne's disease clinical signs and shedding in US cattle. It is recommended for high-prevalence herds, aiding control efforts alongside other measures.

More Related Videos

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Related Experiment Videos

Last Updated: May 28, 2026

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

Area of Science:

Veterinary immunology
Bacteriology
Animal health

Background:

Johne's disease, caused by Mycobacterium avium subsp. paratuberculosis (MAP), poses significant economic challenges in cattle farming.
Control strategies often involve complex management practices that may be resource-intensive.
Existing control measures may not be sufficient in high-prevalence or resource-limited settings.

Purpose of the Study:

To evaluate the efficacy of the Mycopar vaccine in reducing clinical signs and fecal shedding of MAP in cattle.
To assess the vaccine's utility as part of integrated disease control programs.

Main Methods:

The study focuses on the licensed use of Mycopar vaccine in US cattle herds.
Evaluation of vaccine impact on clinical disease and fecal shedding of MAP.
Consideration of the vaccine's role in herds with high MAP prevalence or limited control resources.

Main Results:

The Mycopar vaccine is licensed in the US and demonstrably reduces clinical disease and fecal shedding of MAP.
Vaccination, especially in heavily infected herds, can protect young stock and decrease environmental MAP load.
The vaccine is indicated for herds facing high infection rates or resource constraints for control.

Conclusions:

Mycopar vaccine offers a valuable tool for managing Johne's disease in cattle, particularly in challenging herd situations.
Integration of vaccination with other control measures can enhance protection and reduce disease transmission.
Regulatory guidance from state veterinarians is essential for proper vaccine use, and similar vaccines are used in small ruminant programs internationally.